Study title: A prospective, randomized study to compare ciprofloxacin (either as oral suspension or as IV or sequential IV oral suspension therapy) versus control regimens (either trimethoprim/ sulfamethoxazole oral suspension, cefixime oral suspension, IV ceftazidime, sequential IV ceftazidime trimethoprim/ sulfamethoxazole oral suspension therapy or sequential IV ceftazidime PO cefixime) in the treatment of pediatric patients with complicated urinary tract infections or pyelonephritis.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Bacterial Infections and Mycoses | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: CIPROFLOXACIN | |||||
ATC code: | |||||
Document link: Bayer Pharma_Ciprofloxacin_100169_study_synopsis.pdf | |||||
Document date: 2011-09-07 | |||||
Study number: BAY-O9867-100169 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |